MarketPulse

generic competition

4 articles
The Motley FoolThe Motley Fool··Jack Delaney

J&J Beats Earnings but Faces Patent Cliff Reality Check

Johnson & Johnson exceeded Q1 2026 expectations and raised guidance, though stock declined as Stelara patent losses offset strong drug sales.
JNJdividendgeneric competition
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks for Long-Term Investors

Eli Lilly's GLP-1 success masks valuation risks; P/E of 44 leaves little room for competitive pressure and patent cliff execution.
PFELLYNVOGLP-1 drugsgeneric competition
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Amarin's Vascepa Faces Generic Onslaught: Single-Drug Dependency Poses Existential Risk

Amarin's sole drug Vascepa faces generic competition, causing revenue to plummet 36% to $183 million in 2025, raising serious concerns about the company's single-product vulnerability.
PFEAMRNrevenue declinerestructuring
GlobeNewswire Inc.GlobeNewswire Inc.··Patentvest

Patent Strength, Not Clinical Data, to Drive GLP-1 Market Leadership

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.
PFELLYNVORHHBYAZN+2GLP-1 drugsoral small-molecule